RevBio, Inc. develops Tetranite®, a marine‑inspired synthetic bone adhesive that delivers immediate, wet‑field fixation of bone to bone and bone to metal. The biomaterial combines rapid mechanical stability, controlled biodegradability, and a scaffold effect that is reabsorbed and replaced by new bone, making it the only patented adhesive that meets all regulatory and clinical requirements for bone repair. RevBio’s technology is applicable across orthopedics, dentistry, neurosurgery, veterinary medicine, and trauma care, providing clinicians with a non‑toxic, rapid‑setting solution that supports natural bone remodeling. By leveraging biomimetic chemistry, the company offers a scalable, cost‑effective alternative to traditional bone grafts and fixation devices, driving innovation in regenerative medicine.
RevBio is seeking a Future Opening as a Sr. Research Chemist II to plan and execute physical and chemical characterization projects. The role involves method development, data analysis, presentation to a cross-functional team, and collaboration with engineers and the executive management team. Responsibilities include quality testing, data analysis, and interfacing with external collaborators. The focus is on developing products for medical device applications.
RevBio, Inc. develops Tetranite®, a marine‑inspired synthetic bone adhesive that delivers immediate, wet‑field fixation of bone to bone and bone to metal. The biomaterial combines rapid mechanical stability, controlled biodegradability, and a scaffold effect that is reabsorbed and replaced by new bone, making it the only patented adhesive that meets all regulatory and clinical requirements for bone repair. RevBio’s technology is applicable across orthopedics, dentistry, neurosurgery, veterinary medicine, and trauma care, providing clinicians with a non‑toxic, rapid‑setting solution that supports natural bone remodeling. By leveraging biomimetic chemistry, the company offers a scalable, cost‑effective alternative to traditional bone grafts and fixation devices, driving innovation in regenerative medicine.